Steven Seedhouse
Stock Analyst at Raymond James
(3.54)
# 819
Out of 5,169 analysts
170
Total ratings
48.21%
Success rate
4.73%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRRO Korro Bio | Upgrades: Outperform | $23 | $11.41 | +101.58% | 4 | Mar 13, 2026 | |
| DNTH Dianthus Therapeutics | Upgrades: Strong Buy | $63 → $123 | $78.86 | +55.97% | 5 | Mar 10, 2026 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $9.16 | +183.84% | 2 | Oct 15, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $91.66 | -10.54% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $11.90 | -15.97% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $26.17 | +6.99% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $0.88 | +1,036.36% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $33.55 | +209.99% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $5.81 | +278.66% | 2 | Dec 11, 2024 | |
| PRQR ProQR Therapeutics | Upgrades: Strong Buy | $6 → $14 | $1.72 | +713.95% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $141.29 | -34.18% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $38.32 | +77.45% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $17.89 | +492.51% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $5.55 | +170.27% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $18.29 | +206.18% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $13.21 | +331.49% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $5.99 | +267.28% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.35 | +623.40% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $4.47 | +683.00% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $79.14 | -51.98% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $0.43 | +1,051.81% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $64.72 | -41.29% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $6.55 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.15 | - | 14 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.61 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $10.35 | +2,508.70% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $182.31 | - | 2 | Apr 23, 2020 |
Korro Bio
Mar 13, 2026
Upgrades: Outperform
Price Target: $23
Current: $11.41
Upside: +101.58%
Dianthus Therapeutics
Mar 10, 2026
Upgrades: Strong Buy
Price Target: $63 → $123
Current: $78.86
Upside: +55.97%
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $9.16
Upside: +183.84%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $91.66
Upside: -10.54%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $11.90
Upside: -15.97%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $26.17
Upside: +6.99%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $0.88
Upside: +1,036.36%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $33.55
Upside: +209.99%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $5.81
Upside: +278.66%
ProQR Therapeutics
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.72
Upside: +713.95%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $141.29
Upside: -34.18%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $38.32
Upside: +77.45%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $17.89
Upside: +492.51%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $5.55
Upside: +170.27%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $18.29
Upside: +206.18%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $13.21
Upside: +331.49%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $5.99
Upside: +267.28%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.35
Upside: +623.40%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $4.47
Upside: +683.00%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $79.14
Upside: -51.98%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $0.43
Upside: +1,051.81%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $64.72
Upside: -41.29%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $6.55
Upside: -
Aug 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.15
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.61
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $10.35
Upside: +2,508.70%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $182.31
Upside: -